We are live on
!
Find out more
ECP
Elk Creek Partners Portfolio holdings
AUM
$582M
1-Year Est. Return
10.23%
This Fund
S&P 500
This Quarter
Est. Return
-3.28%
1 Year Est. Return
-10.23%
3 Year Est. Return
+16.39%
5 Year Est. Return
+41.52%
10 Year Est. Return
–
AUM
$1.16B
AUM Growth
-$175M
(-13%)
Cap. Flow
-$71.1M
Cap. Flow
% of AUM
-6.11%
Top 10 Holdings %
Top 10 Hldgs %
23.85%
Holding
127
New
3
Increased
41
Reduced
72
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$16.6M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$11.5M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$10.8M |
| 4 |
Ligand Pharmaceuticals
LGND
|
+$10.1M |
| 5 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$8.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WAGE
WageWorks, Inc.
WAGE
|
+$21M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$13.7M |
| 3 |
MasTec
MTZ
|
+$13.5M |
| 4 |
EFII
Electronics for Imaging
EFII
|
+$13.2M |
| 5 |
IPHI
INPHI CORPORATION
IPHI
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 27.95% |
| 2 | Technology | 17.01% |
| 3 | Industrials | 12.32% |
| 4 | Consumer Discretionary | 11.44% |
| 5 | Communication Services | 11.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PTC Therapeutics
PTCT
$5.64B
| $12.4M | 1.07% |
366,636
+76,486
| +26% | +$3.33M |
|
|
NXGN
27
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $12.2M | 1.05% |
781,647
-124,994
| -14% | -$2.08M |
|
|
28
Karyopharm Therapeutics
KPTI
$43.5M
| $12.2M | 1.05% |
+84,715
| New | +$11.5M |
|
|
EXAS
29
DELISTED
Exact Sciences
EXAS
| $12.2M | 1.05% |
134,682
-1,300
| -1% | -$148K |
|
|
AMRN
30
Amarin Corp
AMRN
$299M
| $12.1M | 1.04% |
39,941
+13,171
| +49% | +$4.6M |
|
|
MAXR
31
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $12.1M | 1.04% |
1,592,748
-7,657
| -0.5% | -$60.7K |
|
|
CLVS
32
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.1M | 1.04% |
3,073,550
+2,046,575
| +199% | +$16.6M |
|
33
EnerSys
ENS
$6.78B
| $12M | 1.03% |
181,952
+54,904
| +43% | +$3.45M |
|
34
Medifast
MED
$109M
| $11.9M | 1.03% |
115,300
+44,880
| +64% | +$4.82M |
|
|
WWE
35
DELISTED
World Wrestling Entertainment
WWE
| $11.9M | 1.03% |
167,822
+8,721
| +5% | +$625K |
|
36
Acadia Healthcare
ACHC
$2.76B
| $11.9M | 1.03% |
383,854
+19,657
| +5% | +$599K |
|
37
Halozyme
HALO
$9.79B
| $11.8M | 1.01% |
758,553
-51,402
| -6% | -$847K |
|
|
MTOR
38
DELISTED
MERITOR, Inc.
MTOR
| $11.7M | 1% |
630,980
+39,268
| +7% | +$795K |
|
|
WAAS
39
DELISTED
AquaVenture Holdings Limited
WAAS
| $11.6M | 1% |
597,437
+48,427
| +9% | +$878K |
|
40
Heron Therapeutics
HRTX
$93.9M
| $11.6M | 1% |
625,636
-42,604
| -6% | -$784K |
|
|
PTLA
41
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $11.6M | 0.99% |
430,825
+13,236
| +3% | +$372K |
|
42
Zurn Elkay Water Solutions
ZWS
$8.38B
| $11M | 0.95% |
845,075
-79,162
| -9% | -$1.06M |
|
|
ICPT
43
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $10.7M | 0.92% |
+161,406
| New | +$10.8M |
|
|
TCF
44
DELISTED
TCF Financial Corporation Common Stock
TCF
| $10.4M | 0.9% |
273,515
+17,111
| +7% | +$681K |
|
45
Enerpac Tool Group
EPAC
$1.83B
| $10.3M | 0.88% |
469,064
+11,003
| +2% | +$252K |
|
46
National Vision
EYE
$1.77B
| $10.2M | 0.88% |
424,595
+65,083
| +18% | +$1.9M |
|
47
Kinsale Capital Group
KNSL
$8.12B
| $10.1M | 0.87% |
98,100
-31,984
| -25% | -$3.07M |
|
48
Surgery Partners
SGRY
$2.01B
| $10.1M | 0.87% |
1,366,741
-87,686
| -6% | -$628K |
|
|
49
MasTec
MTZ
$20.8B
| $10M | 0.86% |
154,731
-230,474
| -60% | -$13.5M |
|
50
NN Inc
NNBR
$255M
| $9.54M | 0.82% |
1,337,366
-60,579
| -4% | -$455K |
|
Similar funds
BAC
AVC
OWD
PP
WWM
JA
PL
EA
Elk Creek Partners's Q3 2019 Portfolio in Review
As of Q3 2019, Elk Creek Partners held 127 positions worth $1.16B, down 13% from $1.34B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Elk Creek Partners withdrew a net $71.1M in Q3 2019, closing 11 positions and reducing 72 holdings. Its most notable exit was WageWorks, Inc., an estimated $21M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 25% a quarter earlier, followed by Technology and Industrials.
Against the trend, Elk Creek Partners opened a new position in Karyopharm Therapeutics worth $12.2M.
- Elk Creek Partners's largest Q3 2019 buy was Karyopharm Therapeutics: 84,715 shares worth $12.2M.
- Elk Creek Partners added most to Clovis Oncology, Inc. in Q3 2019, an estimated $16.6M increase.
- Elk Creek Partners's biggest Q3 2019 reduction was MasTec, cutting an estimated $13.5M.
- Elk Creek Partners fully exited WageWorks, Inc. in Q3 2019, selling an estimated $21M.
- Elk Creek Partners's ten largest holdings make up 24% of its $1.16B portfolio in Q3 2019.
- Elk Creek Partners opened 3 new positions and closed 11 in Q3 2019.
- Elk Creek Partners's portfolio value fell 13% quarter-over-quarter to $1.16B.
Based on Elk Creek Partners's 13F filing for Q3 2019, filed 13 Nov 2019.